

November, 1992, the estimated loss came down to Rs. 11.64 crores, after providing for depreciation of Rs. 30.21 crores.

(c) and (d) The provisional loss can be attributed mainly to availability of imported caprolactam at much cheaper price, forcing FACT to sell its caprolactam at below the remunerative price. The increased input cost in respect of petroleum products and de-control of phosphatic fertilizers has also affected FACT's profitability.

The Company has already represented to the Government for reviewing the customs duty leviable on imported caprolactam and raw materials used for its manufacture. In respect of phosphatic fertilizers, the situation is expected to improve once the prices of these products stabilise in the free market situation.

Non-implementation of provisions of Drug Policy, 1986

3593. SHRI SUDHIR RANJAN MAJUMDAR:

SHRI RAJNI RANJAN SAHU:

Will the PRIME MINISTER be pleased to state:

(a) whether it is a fact that the Drug Policy, 1986 and DPCO 1987 have not been implemented in full;

(b) whether it is a fact that his Ministry have neither implemented phased Manufacturing Programme for Ratio Parameter;

(c) whether it is a fact that his Ministry could get information from drug companies about imports from their principles and their associates;

(d) if so, the names of the companies which provided such information after announcement of the Drug Policy, 1986 and IDPLC, 1987 year-wise so far; and

(e) whether his Ministry have made any study of the informations provided by drug companies, if so, the details thereof and Government's reaction thereto?

THE MINISTER OF STATE IN THE MINISTRY OF CHEMICALS AND FERTILIZERS (SHRI CHINTA MOHAN): (a) and (b) Every proposal received from any company in the organised sector for manufacture of bulk drugs and formulations is cleared only after verifying their compliance of ratio parameters and basic stage of manufacture fixed by the Government respectively. Where there are constraints regarding technology etc., to avoid import of the finished bulk drugs, basic stages are relaxed for specified drugs for specified periods.

(c) to (e) These details have been called for from the concerned companies through their associations, but the response has not been very encouraging.

Over-invoicing of imports by M/s. German Remedies

3594. SHRI H.HANUMANTHAPPA:
SMT. SATYA BAHIN:
SHRI ANANT RAM
JAISWAL:

Will the PRIME MINISTER be pleased to state:

(a) whether it is a fact that M/s. German Remedies are still resorting to over-invoicing of imports of Dipyrindamol, Verapamil Hcl and Nitroso compound which account for about Rs. 6 crores annually;

(b) whether it is a fact that element of over-invoicing is about Rs 3 crores per annum;

(c) whether it is a fact that the company is resorting to this practice by appointing German Managing Director;

(d) what is the name of present Managing Director;

(e) whether it is a fact that Development Commissioner (PI) is also involved in this game plan; and

(f) what steps have been taken to investigate the matter and prevent the outflow of foreign exchange in this manner?